

# आयात शुल्क वाढविल्याने शेतमालाच्या किमती सावरल्या

केंद्राकडून शेतकऱ्यांना दिलासा; आंदोलनाने सरकारला जाग

अशोक तुपे, श्रीरामपूर



शेतमालाच्या कोसळण्याच्या किमती सावरण्यासाठी आयात शुल्क वाढवून निर्यात शुल्क कमी करण्याची मात्रा उपयोगी ठरली. केंद्र सरकारने शेतकऱ्यांच्या वेदना कमी करण्यासाठी उशिरा का होईना निर्णय घेतले आहे. गेल्या त्यामुळे आता शेतमीक्षेत्रातील अस्वस्थता काही प्रमाणात कमी करण्यात यश आले आहे.

त्यामुळे काही शेतमालाच्या किमतीत स्थिरता आली. शहरी मध्यमवर्गीयांचे सरकार अशी टीका खोडून काढण्यासाठी अर्थसंकल्पापूर्वीच हे निर्णय घेण्यात आले होते.

पामतेलावर ५० टक्के तर सोयाबीन तेलावर ४० टक्के शुल्क आकारले. त्यामुळे दर सावरले. विशेष म्हणजे हा निर्णय घेण्यास सरकारला उशिरा झाला. वातून शेतकरी सावरला, असे मत सोयाबीन एक्सपर्ट प्रोफेसर अशोक तुपे यांनी व्यक्त केले. आंतरराष्ट्रीय बाजारपेठेवर सोयाबीनचे दर अवलंबून असतात. आता अर्जेंटिना व ब्राझीलमध्ये उत्पादन घटल्याने तेथे चार हजार रुपये विवटलेने सोयाबीन विकले जात आहे. सोयापेंडचे (डीओसी) दर वाढल्याने सोयाबीनचे दर वाढले. याचा फायदा शेतकऱ्यांना

झाला. पण हा निर्णय लवकर घेणे गरजेचे होते. असे धुळे येथील अईल मिल मालक मनोज अग्रवाल यांचे म्हणणे आहे. मसूर आणि हरभरा उत्पादन यंदा जास्त होणार आहे. बाजारातील हरभरा दर कोसळले होते. त्यामुळे आयात शुल्कात वाढ करण्याची मागणी केली जात होती. सरकारने मसूर व हरबऱ्यावर आता ४० टक्के आयात शुल्क लागू केले आहे. त्याचा फायदा कोसळणारे दर सावरण्यास सुरुवात झाली आहे. डाळीवरील आयात शुल्कात सरकारने प्रथमच मोठी वाढ केली.

**कांदा उत्पादकांना दिलासा**  
कांदाच्या किमती पाडण्यासाठी सरकार किमान निर्यातमुल्यात वाढ करत असते. यंदा सरकारने निर्यातमुल्य (एमईपी) वाढविल्याने कांदाच्या किमती कोसळल्या होत्या. त्यामुळे कांदा उत्पादक शेतकरी संतप्त झाले होते. मात्र या महिन्यात पहिल्याच आठवड्यात किमान निर्यातमुल्य हटविण्याचा निर्णय घेण्यात त्यामुळे कांदा उत्पादकांना दिलासा मिळाला आहे.

# एसटी कर्मचाऱ्यांच्या वेतनवाढीवरील चर्चा फिस्कटली

मान्यताप्राप्त संघटना आपल्या मागणीवर ठाम

प्रतिनिधी, मुंबई



**वेतनवाढीसंदर्भात एसटी**  
महामंडळाच्या मुंबईतील मुख्यालयात कामगार संघटना आणि अधिकाऱ्यांत झालेली चर्चा फिस्कटली. वेतनवाढीवर संघटना आपल्या मागण्यावर ठाम राहिली आणि एसटी महामंडळाने ठेवलेला प्रस्ताव नाकारला. त्यामुळे चर्चेची पहिली फेरी विस्कटल्यानंतर येत्या दहा दिवसांत वेतनवाढीवर चर्चेची दुसरी फेरी होणार आहे.

सातवा वेतन आयोगाप्रमाणेच वेतनवाढ देण्यात यावी, अशी मागणी महाराष्ट्र एसटी कामगार संघटनेसह अन्य पाच संघटनांनी केली आहे. त्यासाठी पुढील चार वर्षांचा वेतन करारही करण्यात आलेला नाही. महामंडळाकडून वेतनवाढीसंदर्भात उच्चस्तरीय समितीही नेमण्यात आली आहे. मात्र या समितीचा अहवाल एसटी संघटनांकडून अमान्य करण्यात आला आहे. वेतनवाढीवर तोडगा निघावा यासाठी गुरुवारी एसटीच्या मुंबई सेन्ट्रल येथील मुख्यालयात एसटी संघटना आणि अधिकाऱ्यांत बैठक घेण्यात आली. यावेळी एसटी प्रशासनाने उच्चस्तरीय

समितीने दिलेला ७४१ कोटी रुपयांचा आर्थिक भाराचा प्रस्ताव स्विकारण्याची विनंती संघटनेला करण्यात आली. परंतु संघटनेकडून त्याला स्पष्ट नकार देण्यात आला.

संघटनेने दिलेला प्रस्ताव ३१ मार्च २०१६ चे मूळ वेतन आणि ३,५०० गुणिले २,५७ यावर चर्चा करण्याची मागणी करण्यात आली. एसटी संघाच्या दुसऱ्या दिवशी एसटी अधिकाऱ्यांनी दिलेला सुमारे १,०७६ कोटींचा प्रस्तावात समाधानकारक वाढ होत नसल्याने संघटनेने प्रशासनाचा सद्याचा प्रस्ताव मान्य करणे कदापि शक्य नसल्याचे महाराष्ट्र एसटी कामगार संघटनेचे अध्यक्ष संदिप शिंदे यांनी सांगितले. यासंदर्भात एसटी आणि संघटनेत आठवडाभरात दुसरी चर्चेची फेरी होणार असल्याची माहिती त्यांनी दिली.

# विदर्भात रविवारी गारांचा पाऊस पडण्याचा हवामान खात्याचा अंदाज

मध्य महाराष्ट्र, मराठवाड्यातील काही भागांमध्ये पावसाची शक्यता

प्रतिनिधी, मुंबई

खात्याकडून सांगण्यात आले आहे. दोन दिवसांच्या दगाळ वातावरणानंतर कोकण, गोवा, मध्य महाराष्ट्र आणि मराठवाडा या भागातील किमान तापमानामध्ये एक ते तीन अंश.सं. घसरण झाली आहे. कोकण आणि गोव्यामध्ये काही तुळकटिकाणी गुरुवारी पावसाच्या सरी पडल्या आहेत. तसेच मुंबईमध्ये ही किमान तापमानामध्ये एक ते दोन अंश.सं. घसरण झाल्याचे नोंदविण्यात आले आहे.

सरकत असल्याने येत्या शनिवारी विदर्भात तुळकटिकाणी मेघगर्जनसह पाऊस पडण्याची शक्यता आहे. रविवारीदेखील ही स्थिती कायम राहणार असून विदर्भामध्ये गारांचा पाऊस पडण्याची शक्यता असल्याचे वेधशाळेकडून सांगण्यात आले आहे. शनिवारपासु पुढील दोन दिवस विदर्भासह मराठवाडा, मध्य महाराष्ट्रमध्येही गडगडाटासह पावसाच्या सरी बरसण्याचा अंदाज हवामान खात्याकडून सांगण्यात आला आहे.

# बी.टी. बियाणांच्या चौकरीसाठी पुन्हा 'एसआयटी'

यवतमाळ: बीटी कापूस बियाणांमध्ये

परवानगी नसलेले तणनाशकाला प्रतिबंध करणारे जीन्स आढळून आल्याने चौकरी करण्यासाठी गुज्याचे गुप्तवाता विभागाचे आयुक्त संजय बर्वे यांच्या अध्यक्षतेखाली शासनाने पुन्हा विशेष तपास पथक अर्थात एसआयटी स्थापना केली

आहे. कृषी व पशुसंवर्धन खात्याने ७ फेब्रुवारीला यासंदर्भात आदेश जारी केले आहेत. समितीचे सदस्य सचिव म्हणून अमरावती विभागाचे कृषी सहसंचालक सुभाष नांगरे यांची नियुक्ती करण्यात आली आहे. समिती एक महिन्याच्या आत अहवाल सादर करणार आहे. अवैधरित्या बी.टी. बियाणांची विक्री करणाऱ्या कंपन्यांची चौकरी करण्याचे आदेश केंद्र सरकारने राज्य सरकारला दिले होते. एसआयटी याबाबत चौकरी करून उपायही सुचवणार आहे.



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.  
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.  
Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com  
CIN: L24299MH1977PLC019982

## Statement of Profit and Loss for the quarter and nine months ended 31 December, 2017

Particulars (Refer notes below)	Standalone (Ind AS)						Consolidated (Ind AS)						Consolidated (IFRS)					
	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)
	Revenue from operations																	
(a) Net sales	14,592.46	16,195.53	21,149.46	45,897.25	57,562.69	76,948.30	21,715.05	22,234.40	24,629.53	67,243.39	65,456.72	89,700.86	21,715.05	22,234.40	24,629.53	67,243.39	65,456.72	89,700.86
(b) Other operating income	973.03	402.59	768.33	1,744.14	2,741.44	4,006.70	321.57	331.50	720.55	989.15	1,828.26	2,155.95	321.57	331.50	720.55	989.15	1,828.26	2,155.95
Revenue from operations	15,565.49	16,598.12	21,917.79	47,641.39	60,304.13	80,955.00	22,036.62	22,565.90	25,350.08	68,232.54	67,284.98	91,856.81	22,036.62	22,565.90	25,350.08	68,232.54	67,284.98	91,856.81
Other income	372.32	563.04	1,063.58	1,361.24	1,984.88	1,482.39	(231.64)	297.26	145.67	218.48	886.52	373.65	(231.64)	297.26	144.93	218.48	885.77	372.90
<b>Total income (I + II)</b>	<b>15,937.81</b>	<b>17,161.16</b>	<b>22,981.37</b>	<b>49,002.63</b>	<b>62,289.01</b>	<b>82,437.39</b>	<b>21,804.98</b>	<b>22,863.16</b>	<b>25,495.75</b>	<b>68,451.02</b>	<b>68,171.50</b>	<b>92,230.46</b>	<b>21,804.98</b>	<b>22,863.16</b>	<b>25,495.01</b>	<b>68,451.02</b>	<b>68,170.75</b>	<b>92,229.71</b>
Expenses																		
Cost of materials consumed	5,224.70	4,848.22	5,615.27	15,073.13	16,941.38	22,420.13	5,051.16	5,443.85	5,600.88	15,351.68	18,358.44	23,548.13	5,051.16	5,443.85	5,600.88	15,351.68	18,358.44	23,548.13
Purchase of stock-in-trade	891.95	664.07	661.52	2,249.08	2,109.63	2,669.96	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(304.49)	584.97	72.99	171.14	(836.19)	(835.17)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)
Employee benefits expense	2,553.98	3,264.26	2,274.07	7,895.91	6,933.45	9,144.71	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06
Finance costs	469.99	474.41	495.39	1,401.76	1,028.81	1,526.02	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18
Depreciation and Amortisation expense	295.53	288.93	263.36	883.86	776.15	1,049.32	753.84	752.28	625.26	2,283.44	1,954.64	2,643.68	895.18	874.05	788.44	2,646.43	2,322.33	3,167.61
Other expenses	4,531.39	3,262.04	4,849.88	12,080.19	12,890.43	18,568.95	6,334.56	5,597.17	7,692.64	18,728.84	20,421.97	28,938.49	6,334.61	5,597.55	7,692.38	18,729.98	20,421.97	28,938.49
<b>Total expenses (IV)</b>	<b>13,663.05</b>	<b>13,386.90</b>	<b>14,232.48</b>	<b>39,755.07</b>	<b>39,843.66</b>	<b>54,543.92</b>	<b>20,268.27</b>	<b>20,132.66</b>	<b>18,942.47</b>	<b>59,742.39</b>	<b>54,987.53</b>	<b>76,506.67</b>	<b>20,409.66</b>	<b>20,254.81</b>	<b>19,105.39</b>	<b>60,106.52</b>	<b>55,355.22</b>	<b>77,030.60</b>
Profit/(loss) before exceptional items and tax (III - IV)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	27,893.47	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	15,723.79	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	15,199.11
Exceptional items (refer note 5)	-	-	-	-	-	2,364.51	-	-	-	-	-	809.49	-	-	-	-	-	2,597.59
Profit/(loss) before tax (V - VI)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	25,258.96	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	14,914.30	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	12,601.52
Tax expense:																		
Current tax	489.59	801.35	1,946.54	1,973.25	4,888.25	6,040.24	529.15	976.19	1,498.51	2,295.47	4,535.33	6,190.43	529.15	976.19	1,498.51	2,295.47	4,535.33	6,177.97
Deferred tax	(155.99)	(305.88)	(310.72)	(654.04)	(302.31)	(1,917.36)	(39.87)	(386.89)	283.76	(109.27)	(626.03)	(2,363.66)	(68.41)	(410.95)	293.14	(183.43)	(692.36)	(2,735.66)
Profit/(loss) for the period (VII - VIII)	1,941.16	3,278.79	7,113.07	7,928.35	17,859.40	21,406.08	1,047.43	2,141.20	4,771.01	6,522.43	9,274.67	11,087.53	934.58	2,043.11	4,597.97	6,232.46	8,972.56	9,159.21
Other comprehensive income																		
A (i) Items that will not be reclassified to profit or loss	(11.92)	(26.09)	(41.17)	(46.61)	(94.20)	(34.40)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)
(ii) Income tax relating to items that will not be reclassified to profit or loss	4.12	9.02	5.87	16.13	23.90	11.70	2.94	(1.02)	12.00	5.90	24.75	13.29	2.94	(1.02)	12.00	5.90	24.75	13.29
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	101.42	(14.41)	(392.75)	(267.50)	473.36	(1,750.00)	62.21	55.73	(333.95)	(232.25)	520.83	(1,758.73)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total comprehensive income</b>	<b>1,933.36</b>	<b>3,261.72</b>	<b>7,077.77</b>	<b>7,897.87</b>	<b>17,789.10</b>	<b>21,383.38</b>	<b>1,148.95</b>	<b>2,176.10</b>	<b>4,354.94</b>	<b>6,292.86</b>	<b>9,695.78</b>	<b>9,303.81</b>	<b>996.89</b>	<b>2,148.15</b>	<b>4,240.70</b>	<b>6,038.14</b>	<b>9,441.14</b>	<b>7,366.76</b>
Total comprehensive income attributable to:																		
- Non-controlling interests	-	-	-	-	-	-	0.64	(0.32)	0.71	0.45	0.71	(0.46)	0.64	(0.32)	0.71	0.45	0.71	(0.46)
- Owners of the Company	1,933.36	3,261.72	7,077.77	7,897.87	17,789.10	21,383.38	1,148.31	2,176.42	4,354.23	6,292.41	9,695.07	9,304.27	996.25	2,148.47	4,239.99	6,037.69	9,440.43	7,367.22
Earning Per Share (of Re 1/- each) (not annualised)																		
Basic Earnings Per Share (in Rupees)	6.88	11.62	25.21	28.10	63.29	75.86	3.71	7.59	16.91	23.12	32.87	39.29	3.31	7.24	16.29	22.09	31.80	32.46
Diluted Earnings Per Share (in Rupees)	6.88	11.62	25.20	28.09	63.28	75.84	3.71	7.59	16.90	23.11	32.86	39.28	3.31	7.24	16.29	22.08	31.79	32.45

**Notes:**  
1. The above results were reviewed by the Audit Committee of the Board at its meeting held on 7 February, 2018 and approved at the meeting of the Board of Directors held on 8 February, 2018.  
2. The results for the quarter and nine months ended 31 December, 2017 presented were subjected to a "Limited Review" by the Statutory auditors of the Company. An unqualified report was issued by them therein.  
3. The Company operates in one reportable business segment i.e., Pharmaceuticals.  
4. As at 31 December, 2017, pursuant to Employee Stock Option Scheme 2003, no options were outstanding. Pursuant to Employee Stock Options Scheme 2016, 582,249 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.  
5. Exceptional items:  
Stand-alone: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to investment and trade receivables from the Company's subsidiary in Venezuela. The Company has not received approvals from the Venezuelan government to repatriate any amounts during the year ended 31 March, 2017 and considering the uncertainty around repatriation, the Company believes it's appropriate to impair such investments and trade receivables from the said subsidiary.  
Consolidated: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to certain intangibles assets under development owing to the Company's future research and development strategy for such products.  
6. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.  
7. Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the nine months ended 31 December, 2017 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for the quarter and nine months ended 31 December, 2017 are not comparable with those of previous periods presented.  
8. The list of subsidiaries as of 31 December, 2017 is provided in Annexure A.

**Annexure A**  
**List of entities included in the consolidated financial results for the quarter and Nine Months ended 31 December 2017.**  
Name of Entities:  
1. Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2. Glenmark Pharmaceuticals Europe Ltd., U.K. 3. Glenmark Pharmaceuticals S.R.O. 4. Glenmark Pharmaceuticals SK, S.R.O. 5. Glenmark Pharmaceuticals S. A. 6. Glenmark Holding S.A. 7. Glenmark Pharmaceuticals S.R.L. 8. Glenmark Pharmaceuticals SP z.o.o. 9. Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10. Glenmark Therapeutics Inc. 11. Glenmark Farmaceutica Ltda 12. Glenmark Generics S.A 13. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14. Glenmark Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16. Glenmark Uruguay S.A. 17. Glenmark Pharmaceuticals Venezuela, C.A 18. Glenmark Dominicana SRL 19. Glenmark Pharmaceuticals Egypt S.A.E

<p><b>DCM LIMITED</b></p> <p>Regd Office: Vikrant Tower, 4, Rajendra Place, New Delhi-110008                  CIN- L74899DL1889PLC000004, Ph: (011)25719967, Fax: (011) 25765214                  Email Id: investors@dcm.in, Website: www.dcm.in</p>							
<p><b>EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE 3<sup>RD</sup> QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017</b>                  (Rs in Lacs)</p>							
Sr. No.	Particulars	Standalone			Consolidated		
		Quarter ended 31.12.2017	Corresponding quarter ended 31.12.2016	Nine months ended 31.12.2017	Quarter ended 31.12.2017	Corresponding quarter ended 31.12.2016	Nine months ended 31.12.2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Total income from operations	21,480	26,268	71,930	21,480	26,268	71,931
2	Net Profit/(Loss) for the period (before tax, exceptional and extraordinary items)	(819)	(623)	(3,655)	(905)	(616)	(3,923)
3	Net Profit/(Loss) for the period before tax (after exceptional and extraordinary items)*	(819)	152	(3,655)	(905)	159	(3,923)
4	Net Profit/(Loss) for the period after tax (after exceptional and extraordinary items)*	(817)	106	(3,653)	(903)	112	(3,921)
5	Total comprehensive income for the period	(867)	90	(3,777)	(953)	95	(4,045)
6	Equity Share Capital	1,867	1,867	1,867	1,867	1,867	1,867
7	Earnings per share (of Rs. 10 each) (Not annualized)						
	(i) Basic	(4.37)	0.57	(19.56)	(4.83)	0.60	(20.99)
	(ii) Diluted	(4.37)	0.57	(19.56)	(4.83)	0.60	(20.99)

\*Includes exceptional items of Rs. 775 lacs for the quarter and nine months ended December 31, 2016 represents the recovery of amount from jointly controlled entity pursuant to the settlement reached by the Company.

**NOTES:**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting(s) held on February 8, 2018. The Limited Review Report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited.
- The above is an extract of the detailed unaudited financial results of the Company for the 3<sup>rd</sup> quarter and nine months ended December 31, 2017 filed with the Stock Exchanges (i.e. BSE Limited and National Stock Exchange of India Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed unaudited financial results of the Company for the 3<sup>rd</sup> quarter and nine months ended December 31, 2017 are available on the Stock Exchanges website(s) <http://www.nseindia.com> and <http://www.bseindia.com> and Company's website [www.dcm.in](http://www.dcm.in).

For and on behalf of the Board  
 For DCM Limited  
 Sd/-  
 Dr. Vinay Bharat Ram  
 Chairman and Managing Director

Place: New Delhi  
 Date: February 08, 2018

 <p><b>TCPL</b> packaging limited</p> <p>CIN: L22210MH1987PLCO44505</p> <p>Regd. Office: Empire Mills Complex, 414, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013                  Telephone: 022-61646000, Website: www.tcpl.in, E-mail: info@tcpl.in</p>			
<p><b>Extract of Unaudited Standalone Financial Results for the Quarter/Nine Months ended 31st December 2017</b></p> <p>(₹ in lacs except per share data)</p>			
Particulars	Quarter ended 31.12.2017	Nine Months ended 31.12.2017	Quarter ended 30.12.2016
	Unaudited	Unaudited	Unaudited
Value of Sales & Services (Revenue)	21143.25	56886.50	17266.55
Less: GST Recovered	2723.72	5367.17	-
<b>Revenue from Operations</b>	<b>18419.53</b>	<b>51519.33</b>	<b>17266.55</b>
Profit before tax	975.32	2296.58	1476.35
Profit for the period	718.02	1616.43	962.88
Total Comprehensive Income (after tax)	725.78	1567.73	948.64
Equity Share Capital	910.00	910.00	870.00
Earnings Per Share (Face value of ₹10/- each) (Not Annualised):			
Basic and Diluted	8.06	18.15	11.07

**Note:**

- The audit committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 7th February 2018. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The above is an extract of the detailed format of the standalone Financial Results for the quarter and nine months ended on 31st December 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the standalone Financial Results for the quarter and nine months ended on 31st December 2017 is available on the Stock Exchanges' websites ([www.bseindia.com](http://www.bseindia.com)/[www.nseindia.com](http://www.nseindia.com)) and the Company's Website [www.tcpl.in](http://www.tcpl.in).

For TCPL Packaging Limited

Saket Kanoria  
 Managing Director  
 DIN:-00040801

Place: Mumbai  
 Date : 07.02.2018



**Registered Office:** B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.  
**Corporate Office:** Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.  
**Tel:** 91 22 4018 9999 **Fax:** 91 22 4018 9986 **Email:** [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com) **Website:** [www.glenmarkpharma.com](http://www.glenmarkpharma.com)  
**CIN:** L24299MH1977PLC019982

## Statement of Profit and Loss for the quarter and nine months ended 31 December, 2017

Particulars (Refer notes below)	Standalone (Ind AS)						Consolidated (Ind AS)						Consolidated (IFRS)					
	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)	Quarter ended 31-12-2017 (Unaudited)	Quarter ended 30-09-2017 (Unaudited)	Quarter ended 31-12-2016 (Unaudited)	Nine Months ended 31-12-2017 (Unaudited)	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)
	Revenue from operations																	
(a) Net sales	14,592.46	16,195.53	21,149.46	45,897.25	57,562.69	76,948.30	21,715.05	22,234.40	24,629.53	67,243.39	65,456.72	89,700.86	21,715.05	22,234.40	24,629.53	67,243.39	65,456.72	89,700.86
(b) Other operating income	973.03	402.59	768.33	1,744.14	2,741.44	4,006.70	321.57	331.50	720.55	989.15	1,828.26	2,155.95	321.57	331.50	720.55	989.15	1,828.26	2,155.95
<b>I Revenue from operations</b>	<b>15,565.49</b>	<b>16,598.12</b>	<b>21,917.79</b>	<b>47,641.39</b>	<b>60,304.13</b>	<b>80,955.00</b>	<b>22,036.62</b>	<b>22,565.90</b>	<b>25,350.08</b>	<b>68,232.54</b>	<b>67,284.98</b>	<b>91,856.81</b>	<b>22,036.62</b>	<b>22,565.90</b>	<b>25,350.08</b>	<b>68,232.54</b>	<b>67,284.98</b>	<b>91,856.81</b>
II Other income	372.32	563.04	1,063.58	1,361.24	1,984.88	1,482.39	(231.64)	297.26	145.67	218.48	886.52	373.65	(231.64)	297.26	144.93	218.48	885.77	372.90
<b>III Total income (I + II)</b>	<b>15,937.81</b>	<b>17,161.16</b>	<b>22,981.37</b>	<b>49,002.63</b>	<b>62,289.01</b>	<b>82,437.39</b>	<b>21,804.98</b>	<b>22,863.16</b>	<b>25,495.75</b>	<b>68,451.02</b>	<b>68,171.50</b>	<b>92,230.46</b>	<b>21,804.98</b>	<b>22,863.16</b>	<b>25,495.01</b>	<b>68,451.02</b>	<b>68,170.75</b>	<b>92,229.71</b>
IV Expenses																		
Cost of materials consumed	5,224.70	4,848.22	5,615.27	15,073.13	16,941.38	22,420.13	5,051.16	5,443.85	5,600.88	15,351.68	18,358.44	23,548.13	5,051.16	5,443.85	5,600.88	15,351.68	18,358.44	23,548.13
Purchase of stock-in-trade	891.95	664.07	661.52	2,249.08	2,109.63	2,669.96	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(304.49)	584.97	72.99	171.14	(836.19)	(835.17)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)
Employee benefits expense	2,553.98	3,264.26	2,274.07	7,895.91	6,933.45	9,144.71	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06
Finance costs	469.99	474.41	495.39	1,401.76	1,028.81	1,526.02	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18
Depreciation and Amortisation expense	295.53	288.93	263.36	883.86	776.15	1,049.32	753.84	752.28	625.26	2,283.44	1,954.64	2,643.68	895.18	874.05	788.44	2,646.43	2,322.33	3,167.61
Other expenses	4,531.39	3,262.04	4,849.88	12,080.19	12,890.43	18,568.95	6,334.56	5,597.17	7,692.64	18,728.84	20,421.97	28,938.49	6,334.61	5,597.55	7,692.38	18,729.98	20,421.97	28,938.49
<b>IV Total expenses (IV)</b>	<b>13,663.05</b>	<b>13,386.90</b>	<b>14,232.48</b>	<b>39,755.07</b>	<b>39,843.66</b>	<b>54,543.92</b>	<b>20,268.27</b>	<b>20,132.66</b>	<b>18,942.47</b>	<b>59,742.39</b>	<b>54,987.53</b>	<b>76,506.67</b>	<b>20,409.66</b>	<b>20,254.81</b>	<b>19,105.39</b>	<b>60,106.52</b>	<b>55,355.22</b>	<b>77,030.60</b>
V Profit/(loss) before exceptional items and tax (III - IV)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	27,893.47	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	15,723.79	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	15,199.11
VI Exceptional items (refer note 5)	-	-	-	-	-	2,364.51	-	-	-	-	-	809.49	-	-	-	-	-	2,597.59
VII Profit/(loss) before tax (V - VI)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	25,258.96	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	14,914.30	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	12,601.52
VIII Tax expense :																		
Current tax	489.59	801.35	1,946.54	1,973.25	4,888.25	6,040.24	529.15	976.19	1,498.51	2,295.47	4,535.33	6,190.43	529.15	976.19	1,498.51	2,295.47	4,535.33	6,177.97
Deferred tax	(155.99)	(305.88)	(310.72)	(654.04)	(302.31)	(1,917.36)	(39.87)	(386.89)	283.76	(109.27)	(626.03)	(2,363.66)	(68.41)	(410.95)	293.14	(183.43)	(692.36)	(2,735.66)
<b>IX Profit/(loss) for the period (VII - VIII)</b>	<b>1,941.16</b>	<b>3,278.79</b>	<b>7,113.07</b>	<b>7,928.35</b>	<b>17,859.40</b>	<b>21,406.08</b>	<b>1,047.43</b>	<b>2,141.20</b>	<b>4,771.01</b>	<b>6,522.43</b>	<b>9,274.67</b>	<b>11,087.53</b>	<b>934.58</b>	<b>2,043.11</b>	<b>4,597.97</b>	<b>6,232.46</b>	<b>8,972.56</b>	<b>9,159.21</b>
X Other comprehensive income																		
A (i) Items that will not be reclassified to profit or loss	(11.92)	(26.09)	(41.17)	(46.61)	(94.20)	(34.40)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)
(ii) Income tax relating to items that will not be reclassified to profit or loss	4.12	9.02	5.87	16.13	23.90	11.70	2.94	(1.02)	12.00	5.90	24.75	13.29	2.94	(1.02)	12.00	5.90	24.75	13.29
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	101.42	(14.41)	(392.75)	(267.50)	473.36	(1,750.00)	62.21	55.73	(333.95)	(232.25)	520.83	(1,758.73)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>XI Total comprehensive income</b>	<b>1,933.36</b>	<b>3,261.72</b>	<b>7,077.77</b>	<b>7,897.87</b>	<b>17,789.10</b>	<b>21,383.38</b>	<b>1,148.95</b>	<b>2,176.10</b>	<b>4,354.94</b>	<b>6,292.86</b>	<b>9,695.78</b>	<b>9,303.81</b>	<b>996.89</b>	<b>2,148.15</b>	<b>4,240.70</b>	<b>6,038.14</b>	<b>9,441.14</b>	<b>7,366.76</b>
XII Total comprehensive income attributable to:																		
- Non-controlling interests	-	-	-	-	-	-	0.64	(0.32)	0.71	0.45	0.71	(0.46)	0.64	(0.32)	0.71	0.45	0.71	(0.46)
- Owners of the Company	1,933.36	3,261.72	7,077.77	7,897.87	17,789.10	21,383.38	1,148.31	2,176.42	4,354.23	6,292.41	9,695.07	9,304.27	996.25	2,148.47	4,239.99	6,037.69	9,440.43	7,367.22
XIII Earning Per Share (of Re 1/- each) (not annualised)																		
Basic Earnings Per Share (in Rupees)	6.88	11.62	25.21	28.10	63.29	75.86	3.71	7.59	16.91	23.12	32.87	39.29	3.31	7.24	16.29	22.09	31.80	32.46
Diluted Earnings Per Share (in Rupees)	6.88	11.62	25.20	28.09	63.28	75.84	3.71	7.59	16.90	23.11	32.86	39.28	3.31	7.24	16.29	22.08	31.79	32.45

**Notes:**

- The above results were reviewed by the Audit Committee of the Board at its meeting held on 7 February, 2018 and approved at the meeting of the Board of Directors held on 8 February, 2018.
- The results for the quarter and nine months ended 31 December, 2017 presented were subjected to a "Limited Review" by the Statutory auditors of the Company. An unqualified report was issued by them therein.
- The Company operates in one reportable business segment i.e., Pharmaceuticals.
- As at 31 December, 2017, pursuant to Employee Stock Option Scheme 2003, no options were outstanding. Pursuant to Employee Stock Options Scheme 2016, 582,249 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- Exceptional items:  
 Stand-alone: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to investment and trade receivables from the Company's subsidiary in Venezuela. The Company has not received approvals from the Venezuelan government to repatriate any amounts during the year ended 31 March, 2017 and considering the uncertainty around repatriation, the Company believes it's appropriate to impair such investments and trade receivables from the said subsidiary.  
 Consolidated: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to certain intangibles assets under development owing to the Company's future research and development strategy for such products.
- The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the nine months ended 31 December, 2017 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for the quarter and nine months ended 31 December, 2017 are not comparable with those of previous periods presented.
- The list of subsidiaries as of 31 December, 2017 is provided in Annexure A.

**Annexure A**  
**List of entities included in the consolidated financial results for the quarter and Nine Months ended 31 December 2017.**

Name of Entities :

- Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.
- Glenmark Pharmaceuticals Europe Ltd., U.K.
- Glenmark Pharmaceuticals S.R.O.
- Glenmark Pharmaceuticals SK, S.R.O.
- Glenmark Pharmaceuticals S. A.
- Glenmark Holding S.A.
- Glenmark Pharmaceuticals S.R.L.
- Glenmark Pharmaceuticals SP z.o.o.
- Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.)
- Glenmark Therapeutics Inc.
- Glenmark Farmaceutica Ltda
- Glenmark Generics S.A
- Glenmark Pharmaceuticals Mexico, S.A. DE C.V.
- Glenmark Pharmaceuticals Peru SAC
- Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda.,